Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Income from Continuing Operations for 3 consecutive years, with 4011000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Income from Continuing Operations fell 130.17% year-over-year to 4011000.0, compared with a TTM value of 12915000.0 through Dec 2024, down 1374.93%, and an annual FY2024 reading of 16817000.0, down 430.52% over the prior year.
  • Income from Continuing Operations was 4011000.0 for Q4 2024 at Oramed Pharmaceuticals, up from 19642000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13296000.0 in Q4 2023 and bottomed at 19642000.0 in Q3 2024.
  • Average Income from Continuing Operations over 3 years is 4512500.0, with a median of 4609500.0 recorded in 2023.
  • Peak annual rise in Income from Continuing Operations hit 342.79% in 2024, while the deepest fall reached 498.11% in 2024.
  • Year by year, Income from Continuing Operations stood at 12326000.0 in 2022, then skyrocketed by 207.87% to 13296000.0 in 2023, then tumbled by 130.17% to 4011000.0 in 2024.
  • Business Quant data shows Income from Continuing Operations for ORMP at 4011000.0 in Q4 2024, 19642000.0 in Q3 2024, and 9204000.0 in Q2 2024.